Why Analysts Are Tuning Out on Roku
Roku shares took a dive on Wednesday after a few analysts came out against the video streaming firm.
All Work
Chris Lange
What to Expect When Dollar General Reports Thursday
Dollar General is scheduled to release its fiscal fourth-quarter financial results before the markets open on Thursday.
Kraft Heinz Explores Breakstone’s Sale: Still Feeling Fallout From Q4?
Kraft Heinz shares saw a marginal gain on Wednesday after it came to light that this food empire has hired a bank for the potential sale of one of its dairy brands.
Nelson Peltz Very High on Aurora Cannabis
Aurora Cannabis is hoping to work collaboratively with notorious activist investor Nelson Peltz to strategically explore potential partnerships. shares jumped early on Wednesday after the Cannabis firm announced that it has appointed the as…
Can Rite Aid Save Itself With This Restructuring?
Rite Aid shares made a sizable jump on Wednesday morning after the firm announced that there would be some changes in its executive leadership as well as some restructuring.
Tuesday’s Biggest Winners and Losers in the S&P 500
Monday was a relatively positive day for the broad U.S. markets. While the S&P 500 and Nasdaq continued to climb this week, the DJIA lagged behind and was negative in the session. Crude oil…
Will ADT Ever Get It Right?
ADT has seen its shares get more or less halved since it has been a public company. The firm originally came public in January 2018, but since then the stock has been on a…
Wedbush’s Apple Predictions for March 25
Apple made waves on Monday when the iPhone giant said that it will be officially announcing its break into the streaming video service on March 25. With this move, Apple will be looking to…
Vadadustat Makes the Case for Blockbuster Status After Japanese Chronic Kidney Disease Studies
Patients suffering anemia due to chronic kidney disease are sure to be content with new positive top-line results from two Phase 3 active-controlled pivotal studies.
Short Sellers Not So High on Marijuana Stocks
The February 28 short interest data have been compared with the previous figures, and short interest moves in these selected marijuana stocks were mixed.
Short Sellers Run for Cover on Major Oil Stocks
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected big oil stocks decreased.
Major Biotechs See a Rising Tide in Short Interest
The February 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Big Pharma Short Interest Backs Off, With One Huge Exception
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
Short Sellers Grow More Selective on Major Semiconductors
The February 28 short interest data have been compared with the previous report. Short interest moves in these selected semiconductor stocks were mixed.
Great News for Adolescents with Moderate to Severe Atopic Dermatitis
In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for with moderate-to-severe atopic dermatitis.
Monday’s Biggest Winners and Losers in the S&P 500
Monday was a positive day for the broad U.S. markets. The S&P 500 and Dow Jones singlehandedly wiped out all of last week’s loss in Monday’s session alone. After suffering another 737 crash, Boeing…
Why Investors Are Hyped for Tonix Pharma’s PTSD Late-Stage Trial
Tonix Pharma shares made a solid gain on Monday after the firm announced that it is beginning to enroll patients in its late-stage study of Tonmya for the treatment of post-traumatic stress disorder.
Are Mellanox Shareholders Getting Enough in the Acquisition?
Mellanox shares jumped on Monday after the announced that Nvidia would be acquiring the firm.
What These 2 Neurodegenerative Studies Could Mean for the Future of Axovant
Axovant Sciences has produced results from two separate studies related to neurodegenerative diseases, and its shares had a sharp gain to start off the week.
10 Reasons Merrill Lynch Is Now Bullish on Apple
Merrill Lynch has come out in favor of Apple, and the analyst sees a very bullish future for the company for a number of reasons.